Fresh off the research radar — new HBOT science just published, summarized for our community.
Title:
New review shows how hyperbaric oxygen could strengthen chemotherapy, radiotherapy and immunotherapy
What this review is about
Cancer tumours often grow in low-oxygen environments, a problem called hypoxia.
Hypoxia is one of the biggest reasons why cancer treatments fail or become less effective.
This new scientific review looked at how hyperbaric oxygen therapy may help overcome this oxygen shortage and make many cancer treatments work better.
The paper connected findings from biology, preclinical studies and early clinical trials, showing how HBOT can influence multiple treatment pathways at once.
Key insights from the review
1. HBOT re-oxygenates tumours
Hyperbaric oxygen increases dissolved oxygen in the blood far more than normal breathing can.
This reaches deep into tumour tissue and helps:
- reduce hypoxia
- make cancer cells less resistant
- improve therapeutic response
2. HBOT makes chemotherapy more effective
Oxygenated tumour tissue allows chemotherapy drugs to penetrate deeper and work better.
Hypoxic cancer cells often resist chemotherapy — HBOT helps reverse that.
3. HBOT increases the impact of radiotherapy
Radiation is far more effective when oxygen is present.
HBOT enhances radiation-induced DNA damage in cancer cells, making the treatment stronger.
4. HBOT supports immunotherapy
Hypoxia suppresses the immune system around the tumour.
Re-oxygenating the area improves immune activation and helps treatments like immune checkpoint inhibitors work more effectively.
5. HBOT affects important biological pathways
The review highlights several mechanisms influenced by HBOT:
- oxidative stress regulation
- ferroptosis (a form of cell death relevant to killing cancer cells)
- angiogenesis (blood vessel formation)
- cancer stem cell behaviour
- tumour microenvironment remodeling
These pathways are normally involved in treatment resistance — HBOT helps counteract them.
Important nuance: the paper also discusses challenges
The authors emphasise that we still need:
- clearer dose-response studies
- better understanding of long-term safety in specific cancers
- insight into when HBOT’s pro-angiogenic effects might be helpful or not
- precision tools to identify which patients benefit most
This is a balanced review, not hype — it acknowledges potential risks and the need for more well-designed trials.
Why this matters
Cancer hypoxia is one of the hardest problems in oncology.
Any therapy that reduces hypoxia can potentially:
- increase treatment success
- reduce resistance
- improve patient outcomes
HBOT is compelling because it is:
- non-invasive
- well-tolerated
- able to target multiple mechanisms simultaneously
The authors suggest that integrating HBOT into multi-modal cancer treatment could become an important strategy in personalised medicine.
Takeaway for THE community
This 2025 review positions hyperbaric oxygen therapy as a rising supportive treatment in oncology.
Not to replace standard therapies — but to make them work better by breaking the hypoxia barrier.
HBOT may help:
- chemotherapy reach deeper into tumours
- radiotherapy damage cancer cells more effectively
- immunotherapy activate the immune system more strongly
- reduce cancer’s ability to resist treatment
HBOT Radar will continue tracking the latest evidence on how hyperbaric oxygen fits into future cancer therapy.
Study link: https://pubmed.ncbi.nlm.nih.gov/41172962/
